Pharma: Page 22
-
Getty Images
Roche, following setbacks, turns to its next Alzheimer’s drug
Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.
By Jonathan Gardner • March 11, 2024 -
Mario Tama via Getty Images
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
By Michael Gibney • March 11, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
FDA delays decision on Lilly’s closely watched Alzheimer’s drug
The agency expects to convene a group of outside experts to more closely scrutinize the safety and efficacy of the medicine, donanemab, pushing back the timing of its potential approval.
By Jonathan Gardner • March 8, 2024 -
Sean Gallup via Getty Images
Bayer isn’t splitting up, for now
Company shares fell after executives disclosed plans to, at least temporarily, keep its three main divisions under one roof.
By Jacob Bell • March 5, 2024 -
Anna Moneymaker via Getty Images
CVS, Walgreens to start selling abortion pill in some states
The two pharmacy retailers will begin dispensing mifepristone in some states weeks before the start of a Supreme Court case that will decide how widely the pill can be accessed.
By Delilah Alvarado • March 4, 2024 -
Getty Images
AstraZeneca’s drug pricing lawsuit dismissed by federal judge
The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.
By Jonathan Gardner • March 4, 2024 -
Getty Images
Bayer pays $310M to buy into BridgeBio heart drug
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
By Ben Fidler • March 4, 2024 -
Adobe Stock / yj
Sponsored by PanalgoQ&A: How AI and ML are reshaping the research landscape
Panalgo’s Meg Richards and Mike Munsell discuss how AI and ML are transforming the healthcare research landscape.
By Meg Richards, PhD, MBH Executive Director of Solutions, Panalgo With Mike Munsell, Director of Research, Panalgo • March 4, 2024 -
Spencer Platt via Getty Images
Pfizer, looking for a jumpstart, leans into cancer drug research
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
By Jonathan Gardner • March 1, 2024 -
Kevin C. Cox via Getty Images
CDC panel mulls changes to RSV vaccine recommendation
The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.”
By Delilah Alvarado • March 1, 2024 -
Sara Silbiger via Getty Images
Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt
The companies didn’t reveal their planned price for Simlandi, which will be the 10th Humira copycat to reach the U.S. market.
By Jonathan Gardner • Feb. 26, 2024 -
Permission granted by PHC Corporation of North America
Sponsored by PHC Corporation of North AmericaChoosing laboratory equipment with workplace experience in mind
Making equipment choices with employee experience in mind can help researchers build top-performing teams while enhancing operational efficiencies.
Feb. 26, 2024 -
Peddalanka Ramesh Babu via Getty Images
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
European drug regulators recommended clearing J&J and Legend Biotech's Carvykti for use as early as after first relapse, potentially giving the therapy an advantage over Bristol Myers’ Abecma.
By Ned Pagliarulo • Feb. 23, 2024 -
Getty Images
Outgoing AbbVie CEO leaves a divisive Humira legacy and lasting impact on pharma
Richard Gonzalez led AbbVie to become one of the largest pharmaceutical firms, but the company's pricing and patent tactics brought criticism, too.
By Michael Gibney • Feb. 22, 2024 -
Win McNamee via Getty Images
Rick Gonzalez, longtime AbbVie CEO, to step down in July
The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael.
By Jonathan Gardner • Feb. 20, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindHere are 7 practical ways asynchronous advisory programs can make an impact in 2024
Can asynchronous advisory programs can add distinct value to your strategic mix? Yes! Here's how.
Feb. 20, 2024 -
Courtesy of Astellas Pharma
Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies
Kelonia will receive $40 million upfront through the partnership, and could receive $35 million more if Astellas opts into another program.
By Gwendolyn Wu • Feb. 16, 2024 -
Kevin Dietsch via Getty Images
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.
By Jonathan Gardner • Feb. 8, 2024 -
Mario Tama via Getty Images
Obesity drug mania takes over Amgen’s earnings call
Analysts pressed company executives Tuesday on the potential of its GLP-1 drug for weight loss, early-stage results for which were published this week.
By Ned Pagliarulo • Feb. 7, 2024 -
Christopher Furlong via Getty Images
AstraZeneca to invest $300M in US cell therapy plant
The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.
By Kristin Jensen • Feb. 7, 2024 -
Getty Images
Lilly sales surge on obesity, diabetes drug demand
The company also reported trial results suggesting tirzepatide, the drug Lilly now sells as Mounjaro and Zepbound, could treat a common liver disease.
By Jonathan Gardner • Feb. 6, 2024 -
Courtesy of Johnson & Johnson
J&J says top drug prospect works across autoimmune disorders
The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.
By Jacob Bell • Feb. 5, 2024 -
Courtesy of Sanofi
Sanofi appoints Nestlé executive as new finance chief
François-Xavier Roger will replace current CFO Jean-Baptiste Chasseloup de Chatillon as Sanofi continues a research pivot and cost-cutting drive.
By Delilah Alvarado • Feb. 1, 2024 -
Getty Images
Merck keeps deal focus with Keytruda patent cliff on horizon
The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.
By Ned Pagliarulo • Feb. 1, 2024 -
Courtesy of Roche
Roche shuffles early stage pipeline as it joins obesity rush
Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.
By Jonathan Gardner • Feb. 1, 2024
Previous
